
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen exhibits a positive financial outlook driven by its robust pipeline and significant growth in research and development, with management forecasting an increase exceeding 20% in R&D expenditure for 2025 compared to 2024. The company's strong sales momentum is evidenced by Uplizna's approximately 58% growth in June 2025 compared to the previous quarter and a 40% increase relative to June 2024. These factors, along with ongoing advancements in its therapeutic offerings, support a compelling case for potential multiple expansion, as reflected in an expected EV/2026E EBITDA of around 13x.
Bears say
Amgen's financial outlook appears negative due to increasing competition in the biotechnology sector, particularly with the introduction of biosimilars and alternative treatments for key therapies, which may erode market share and pricing power. Additionally, the company's reliance on a limited number of flagship drugs, some of which are facing patent expirations and declining sales, raises concerns about sustained revenue growth. Furthermore, the significant costs associated with recent acquisitions and the ongoing need for extensive research and development investments may place pressure on profitability in the near term.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares